React conquered XSS? Think again. That's the reality facing JavaScript developers in 2025, where attackers have quietly evolved their injection techniques to exploit everything from prototype ...

Recent presidential elections have featured a lot of continuity. In a politically polarized America, the vast majority of voters stick with the same party from election to election. But in a closely ...

The composition of Republican and Democratic voters in the United States has changed since the 2020 presidential election, and the shifts have been even larger since the 2016 contest. Donald Trump’s ...

Lucas Kloberdanz-Dyck is a writer for Collider. He grew up creating lists, stories, and worlds, which led to his love of anime and video games. He attended Sheridan College where he earned an Honours ...

Join InSight Crime’s regional experts for an exclusive virtual panel examining 2025 homicide data across 31 countries, how organized crime shaped national trends, and what the widespread use of states ...

PepsiCo's earnings topped Wall Street's estimates, but the company's revenue missed expectations. Demand for its snacks and drinks declined in North America. In this article PepsiCo reported mixed ...

Cisco subsidiary ThousandEyes released its list of the most notable Internet outages and application issues of last year, along with recommendations to help ITOps teams improve digital resilience.

For stock investors, 2024 was an expectedly great year. Behind the continued bull market for stocks was solid economic growth, falling inflation, Federal Reserve interest-rate cuts, and healthy ...

Crude oil markets experienced limited activity over the past week as the holiday season reduced trading volumes. With markets closed for New Year’s Day, price movement was minimal, reflecting the lack ...

Amid another year of solid performance in the stock market, AppLovin APP performed best in the Morningstar US Large-Mid Cap Index. The mobile app technology company surged over 700% in 2024 after ...

The FDA approved 50 new therapeutics in 2024, with green lights for a novel schizophrenia drug, a first NASH medicine and much more. The FDA’s Center for Drug Evaluation and Research (CDER) approved ...